Overview

Stock Quote

  • Robust, diversified pipeline based on proprietary technologies
  • Immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for Phase 3 program in metastatic melanoma and near-term development milestones
  • Cell therapeutic applicable for multiple cardiovascular indications with ongoing Phase 2 study for acute myocardial infarction
  • Immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders
  • Bicoastal capabilities innovating discovery, development, manufacturing, and delivery of cell-based therapies
  • Highly experienced management and scientific team

Investor Events

2015 Marcum MicroCap Conference

May 28, 2015 - 11:00 AM ET
Grand Hyatt New York, NY

Presenter: Dr. David J. Mazzo, Chief Executive Officer
Topic: Company Presentation


Press Releases

Investor Presentation

DOWNLOAD THE PRESENTATION IN PDF FORMAT »